

## **Antibody to VLA-4, but not to L-selectin, protects neuronal M2 muscarinic receptors in antigen-challenged guinea pig airways.**

A D Fryer, ... , D A Steeber, B S Bochner

*J Clin Invest.* 1997;**99**(8):2036-2044. <https://doi.org/10.1172/JCI119372>.

### Research Article

Antigen challenge of sensitized guinea pigs decreases the function of inhibitory M2 muscarinic autoreceptors on parasympathetic nerves in the lung, potentiating vagally induced bronchoconstriction. Loss of M2 receptor function is associated with the accumulation of eosinophils around airway nerves. To determine whether recruitment of eosinophils via expression of VLA-4 and L-selectin is critical for loss of M2 receptor function, guinea pigs were pretreated with monoclonal antibodies to VLA-4 (HP1/2) or L-selectin (LAM1-116). Guinea pigs were sensitized and challenged with ovalbumin, and M2 receptor function was tested. In controls, blockade of neuronal M2 muscarinic receptors by gallamine potentiated vagally induced bronchoconstriction, while in challenged animals this effect was markedly reduced, confirming M2 receptor dysfunction. Pretreatment with HP1/2, but not with LAM1-116, protected M2 receptor function in the antigen-challenged animals. HP1/2 also inhibited the development of hyperresponsiveness, and selectively inhibited accumulation of eosinophils in the lungs as measured by lavage and histology. Thus, inhibition of eosinophil influx into the lungs protects the function of M2 muscarinic receptors, and in so doing, prevents hyperresponsiveness in antigen-challenged guinea pigs.

**Find the latest version:**

<https://jci.me/119372/pdf>



# Antibody To VLA-4, but Not To L-Selectin, Protects Neuronal M<sub>2</sub> Muscarinic Receptors In Antigen-challenged Guinea Pig Airways

Allison D. Fryer,\* Richard W. Costello,\* Bethany L. Yost,\* Roy R. Lobb,<sup>§</sup> Thomas F. Tedder,<sup>||</sup> Douglas A. Steeber,<sup>||</sup> and Bruce S. Bochner<sup>‡</sup>

\*Department of Environmental Health Sciences, School of Hygiene and Public Health, and <sup>‡</sup>Division of Clinical Immunology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland 21205; <sup>§</sup>Biogen Inc., Cambridge, Massachusetts 02142; and <sup>||</sup>Department of Immunology, Duke University Medical Center, Durham, North Carolina 27710

## Abstract

Antigen challenge of sensitized guinea pigs decreases the function of inhibitory M<sub>2</sub> muscarinic autoreceptors on parasympathetic nerves in the lung, potentiating vagally induced bronchoconstriction. Loss of M<sub>2</sub> receptor function is associated with the accumulation of eosinophils around airway nerves. To determine whether recruitment of eosinophils via expression of VLA-4 and L-selectin is critical for loss of M<sub>2</sub> receptor function, guinea pigs were pretreated with monoclonal antibodies to VLA-4 (HP1/2) or L-selectin (LAM1-116). Guinea pigs were sensitized and challenged with ovalbumin, and M<sub>2</sub> receptor function was tested. In controls, blockade of neuronal M<sub>2</sub> muscarinic receptors by gallamine potentiated vagally induced bronchoconstriction, while in challenged animals this effect was markedly reduced, confirming M<sub>2</sub> receptor dysfunction. Pretreatment with HP1/2, but not with LAM1-116, protected M<sub>2</sub> receptor function in the antigen-challenged animals. HP1/2 also inhibited the development of hyperresponsiveness, and selectively inhibited accumulation of eosinophils in the lungs as measured by lavage and histology. Thus, inhibition of eosinophil influx into the lungs protects the function of M<sub>2</sub> muscarinic receptors, and in so doing, prevents hyperresponsiveness in antigen-challenged guinea pigs. (*J. Clin. Invest.* 1997. 99:2036–2044.)

**Key words:** airway hyperresponsiveness • eosinophils • HP1/2 • hyperreactivity • inflammation

## Introduction

Inhalation of aerosolized antigen by sensitized animals or by man causes immediate bronchoconstriction, followed by a period when the lung is hyperresponsive, or abnormally sensitive to a variety of bronchoconstrictive stimuli (1). Antigen-induced hyperresponsiveness in humans and in experimental animals is associated with an influx of inflammatory cells, especially eosinophils, into the airways (2–7). Eosinophils seem to be particu-

larly important for the development of hyperresponsiveness, since pharmacological or immunological depletion or prevention of eosinophil accumulation in the lungs prevents antigen-induced hyperresponsiveness (5, 8–11).

In the lungs, the parasympathetic nerves in the vagi provide the dominant autonomic control of airway smooth muscle (12). These nerves release acetylcholine onto M<sub>3</sub> muscarinic receptors on the smooth muscle, causing contraction of the muscle, and bronchoconstriction (13, 14). Normal control of acetylcholine release from the parasympathetic nerves is provided by inhibitory M<sub>2</sub> muscarinic receptors located on the parasympathetic nerves (15, 16). Stimulating these neuronal M<sub>2</sub> muscarinic receptors with agonists (including acetylcholine) inhibits the release of acetylcholine, and decreases vagally induced bronchoconstriction. Conversely, blocking the neuronal M<sub>2</sub> muscarinic receptors using the selective antagonist gallamine, potentiates vagally induced bronchoconstriction (15). These inhibitory M<sub>2</sub> receptors are important modulators of neurotransmitter release since blocking their function increases acetylcholine release threefold (17), and increases vagally induced bronchoconstriction 5–10-fold (15, 16).

Histological examination of airways from antigen-challenged guinea pigs shows that eosinophils appear to congregate around the nerves, and are occasionally seen within the nerve bundles (18, 19). The presence of eosinophils around the nerves, and thus around the M<sub>2</sub> muscarinic receptors, suggests a mechanism for antigen-induced hyperreactivity. Eosinophils release eosinophil major basic protein and eosinophil peroxidase, both of which are endogenous antagonists of inhibitory neuronal M<sub>2</sub> muscarinic receptors (20). Thus, eosinophil products may increase acetylcholine release from the parasympathetic nerves by acting as endogenous antagonists of the inhibitory M<sub>2</sub> receptors.

The function of the neuronal M<sub>2</sub> muscarinic receptors is markedly impaired after antigen challenge of sensitized animals (16). Loss of function of these inhibitory M<sub>2</sub> receptors is characterized by airway hyperresponsiveness to electrical stimulation of the vagus nerves, and by a marked attenuation of the potentiation of vagally induced bronchoconstriction by gallamine. Treatment of antigen-challenged animals with heparin or poly-L-glutamate acutely restores neuronal M<sub>2</sub> muscarinic receptor function, and reduces the hyperresponsiveness (21). Since both of these substances bind to and neutralize major basic protein in vitro (22, 23), this suggests a role for eosinophil proteins in loss of M<sub>2</sub> muscarinic receptor function.

Despite the consistent findings of tissue eosinophilia in allergic diseases of the airways, the mechanisms by which eosinophils are selectively recruited to these tissue sites remains incompletely defined. One possible pathway suggested by recent studies involves differences in adhesion molecules expressed on leukocyte subtypes (24). For example, the  $\beta$ 1 integrin very

Address correspondence to Allison D. Fryer, Department of Environmental Health Sciences, School of Hygiene and Public Health, Johns Hopkins University, 615 N. Wolfe Street, Baltimore, MD 21205. Phone: 410-955-3612; FAX: 410-955-0299.

Received for publication 2 August 1996 and accepted in revised form 11 February 1997.

*J. Clin. Invest.*

© The American Society for Clinical Investigation, Inc.

0021-9738/97/04/2036/09 \$2.00

Volume 99, Number 8, April 1997, 2036–2044

late activation antigen-4 (VLA-4)<sup>1</sup> is expressed on eosinophils, but not on neutrophils (25–28). Thus, VLA-4 expression allows eosinophils to adhere to their endothelial counterreceptor, vascular cell adhesion molecule (VCAM-1) (29), while neutrophils cannot. This interaction also enhances activation of eosinophils (30). Endothelial expression of VCAM-1 is increased at sites of tissue eosinophilia, including experimental late-phase reactions of the airways in nasal polyps, and in patients with active asthma (31–36), lending further support to the hypothesis that these adhesion molecules contribute to selective eosinophil recruitment *in vivo*.

HP1/2 is a mouse monoclonal antibody against human VLA-4 that inhibits eosinophil migration into skin after intradermal challenge of sensitized guinea pigs with antigen (37). In addition, pretreatment with HP1/2 before antigen challenge of sensitized guinea pigs prevents both the accumulation of eosinophils in the lung and hyperresponsiveness normally seen after antigen challenge (11, 37). The experiments reported here were carried out to establish whether pretreatment with an antibody to VLA-4 can also protect the neuronal M<sub>2</sub> muscarinic receptor from antigen challenge, and to determine whether it is specifically eosinophils that are responsible for loss of M<sub>2</sub> muscarinic receptor function and for the development of hyperreactivity in antigen-challenged guinea pigs. In addition, we have compared the effect of the VLA-4 antibody to that of an anti-L-selectin antibody, LAM1-116, because L-selectin is known to function in eosinophil adhesion-related responses *in vitro* and *in vivo* (38, 39).

## Methods

**Animals.** Specific pathogen-free Dunkin-Hartley guinea pigs were used (all females, 180–200 g; Hilltop Lab Animals, Inc., Scottsdale, PA). Animals were shipped in filtered crates, and were kept in high-efficiency particulate-filtered (HEPA) air on a normal diet (Prolab; Agway, Syracuse, NY). Guinea pigs were handled in accordance with the standards established by the USA Animal Welfare Acts set forth in National Institute of Health guidelines, and the Policy and Procedures Manual published by the Johns Hopkins University School of Hygiene and Public Health Animal Care and Use Committee.

**Drugs.** Atropine, gallamine, guanethidine, isoproterenol, ovalbumin, suxamethonium, and urethane were purchased from Sigma (St. Louis, MO). All drugs were dissolved and diluted in 0.9% NaCl except the aerosolized ovalbumin, which was dissolved in sterile H<sub>2</sub>O.

**Monoclonal antibodies.** HP1/2, a mouse IgG1 anti-human VLA-4 monoclonal antibody (mAb) that is cross-reactive with guinea pig VLA-4, was generated endotoxin-free for use in these studies as described (37).

LAM1-116, a mouse IgG1 anti-human L-selectin monoclonal was generated by immunizing L-selectin-deficient mice with human L-selectin (40, 41). The LAM1-116 mAb reacts specifically with human, mouse, rat, and guinea pig L-selectin, and does not bind human E or P-selectin. This monoclonal binds to the lectin domain of human L-selectin, and blocks the binding of 95% of human and mouse L-selectin to endothelial venules of peripheral lymph nodes from rat and mouse (Steeber, D.A., and T.F. Tedder, unpublished data). Milligram quantities of endotoxin-free antibodies were purified from sterile mouse ascites fluid by salt extraction followed by anion-exchange chromatography.

**Time course of sensitization and challenge with antigen.** Guinea pigs were injected intraperitoneally with either saline (control) or 10

mg·kg<sup>-1</sup> ovalbumin on days 1, 3, and 5 (sensitized) (16). 21 d later animals were antigen-challenged by exposure on four consecutive days to an aerosol of 2.5% ovalbumin for either 5 min, or until signs of respiratory distress appeared. On day 1 of antigen challenge only, pyrilamine (1 mg·kg<sup>-1</sup>) was administered intraperitoneally to all animals 60 min before exposure to aerosolized ovalbumin. 24 h after the last antigen challenge, the function of the neuronal M<sub>2</sub> muscarinic receptors, and the inflammatory cells in blood, in bronchoalveolar lavage, and in airway tissue, were measured.

Two groups of guinea pigs were sensitized with ovalbumin as above, but were treated with either HP 1/2 (4 mg·kg<sup>-1</sup> ip) or LAM1-116 (4 mg·kg<sup>-1</sup> ip) 1 h before challenge. Animals received four separate injections, one per day on each of the four challenge days. These doses were selected based on results from pilot studies in four animals with HP1/2, demonstrating that at the end of this protocol serum levels of mouse monoclonal antibodies, as determined by ELISA, were sufficient to saturate surface ligands (33±10 µg/ml; see below).

**Anesthesia.** Guinea pigs were anesthetized with 1.5 g·kg<sup>-1</sup> urethane intraperitoneally. While this dose of urethane produced a deep anesthesia lasting 8–10 h, none of the experiments lasted for longer than 3 h (42).

A carotid artery was cannulated for measurement of blood pressure using a transducer (Spectramed, Oxnard, CA), and the heart rate was derived from the blood pressure using a tachograph. Both vagus nerves were cut, and the distal ends were placed on electrodes and bathed in a pool of liquid paraffin. The animals were paralyzed by infusing suxamethonium (10 µg·kg<sup>-1</sup> min<sup>-1</sup>). A positive pressure, constant volume rodent ventilator (Harvard Apparatus, Inc., South Natick, MA) was used to artificially ventilate the animals via a tracheal cannula at a tidal volume of 1.0 ml/100 g body wt and 100 breaths·min<sup>-1</sup>. Pulmonary inflation pressure (Ppi) was measured at the trachea using a pressure transducer (DTX, Spectramed). A positive pressure of 80–150 mm H<sub>2</sub>O was needed to adequately ventilate the animals. Signals were recorded on a polygraph (Grass Instrument Co., Quincy, MA). Bronchoconstriction was measured as the increase in Ppi over the basal inflation pressure produced by the ventilator (43). The sensitivity of the method was increased by taking the output Ppi signal from the driver of one channel to the input of the preamplifier of a different channel on the polygraph. Thus, baseline Ppi was recorded on one channel, and increases in Ppi above the baseline were recorded on a separate channel. This method provided a way to balance the baseline Ppi signal on the latter channel, and to record the increase in Ppi at a greater amplification. With this method, increases in Ppi as small as 2–3 mm H<sub>2</sub>O could be accurately recorded.

**Measurement of hyperreactivity.** All animals were pretreated with guanethidine (5 mg·kg<sup>-1</sup> ip) to deplete noradrenaline (44). Electrical stimulation of both vagus nerves produced bronchoconstriction (measured as an increase in Ppi) and bradycardia. Pulse duration (0.2 ms), the volts used (10 V), and the train stimulus (5 s) were kept constant, while the frequency was increased from 2–15 Hz. Supramaximal voltages were not used since increasing the volts above 10 caused severe bradycardia. Likewise, frequencies above 15 Hz were also not used because of the severe bradycardia. The vagus nerves were stimulated at 2-min intervals. Vagally induced bronchoconstriction was measured as the peak increase in Ppi above basal inflation pressure in mm H<sub>2</sub>O.

**Measurement of M<sub>2</sub> muscarinic receptor function.** Electrical stimulation of both vagus nerves produced bronchoconstriction (measured as an increase in Ppi) and bradycardia. The nerves were stimulated at 1-min intervals. The frequency (15 Hz), pulse duration (0.2 ms), and train stimulus (5 s) were kept constant for each group of animals. All animals were pretreated with guanethidine (5 mg·kg<sup>-1</sup> ip) to deplete noradrenaline (44). Before giving gallamine, the voltage was chosen to give a bronchoconstriction of 15–20 mm H<sub>2</sub>O (9.5±0.78 V). Cumulative doses of gallamine (0.1–10.0 mg·kg<sup>-1</sup>) were administered, and the effects of gallamine on vagally induced bronchoconstriction were measured as a ratio of bronchoconstriction in the presence of gallamine to the bronchoconstriction in the absence of gallamine.

1. *Abbreviations used in this paper:* Ppi, pulmonary inflation pressure; VCAM-1, vascular cell adhesion molecule-1; VLA-4, very late activation antigen-4.

At the end of each experiment, atropine ( $1 \text{ mg}\cdot\text{kg}^{-1}$  iv) blocked all responses to vagal nerve stimulation, demonstrating that bronchoconstriction was mediated via muscarinic receptors. A few sensitized guinea pigs were randomly selected and given ovalbumin ( $1 \text{ mg}\cdot\text{kg}^{-1}$  iv) to demonstrate that the sensitized animals were indeed sensitized.

**Bronchoalveolar lavage and peripheral blood analysis.** After the function of the neuronal  $M_2$  muscarinic receptor had been measured using gallamine, bronchoalveolar lavage (BAL) was performed in situ via the tracheal cannula. The lungs were lavaged with 5 aliquots of 10 ml warm PBS containing 3 mM EDTA and  $100 \mu\text{M}$  isoproterenol (pH 7.2–7.4) (45). The recovered lavage fluid (40–45 ml) was centrifuged, the cells were resuspended in 20 ml of PBS, and total cells were counted using a hemacytometer. Aliquots of the cell suspension were cytospun onto glass slides, stained, (Diff-Quik<sup>®</sup>; Scientific Products, McGaw Park, IL) and counted to obtain cell differentials (46). Whole blood was taken from the carotid cannula via a heparinized syringe, and was placed in 0.1 N HCl solution to lyse red blood cells. Total peripheral blood leukocytes were counted with a hemacytometer, and cell differentials were obtained from a blood smear.

**Flow cytometry.**  $100\text{-}\mu\text{l}$  aliquots of EDTA-anticoagulated guinea pig blood from untreated animals were incubated with saturating concentrations ( $5 \mu\text{g/ml}$ ) of HP1/2, LAM1-116, or with identical concentrations of an irrelevant mouse IgG1 monoclonal (Coulter Immunology, Hialeah, FL) essentially as described (47). After erythrocyte lysis, cells were incubated with saturating concentrations of FITC-conjugated polyclonal goat anti-mouse IgG antiserum (Caltag Laboratories, South San Francisco, CA), fixed, and neutrophils and lymphocytes were analyzed by appropriate gating for immunofluorescence using a flow cytometer (EPICS; Coulter) after excitation at 488 nm. At least 5,000 events were collected. For comparison in experiments where animals received antibody treatments in vivo, leukocytes were obtained at the end of the experiments, and attachment of monoclonal antibodies was detected by the addition of the FITC-conjugated secondary antibody alone; controls consisted of no secondary antibody (see Fig. 1). To further investigate whether antibody levels were saturating and were maintained in vivo, separate aliquots of cells from antibody-treated animals were preincubated in vitro with saturating concentrations of monoclonal antibody, and were processed in the same manner as the cells from the nonantibody-treated animals. This approach confirmed that saturating levels of antibody were already present on the circulating cells (i.e., no increase in labeling was observed), and that antibody treatment in vivo did not result in any detectable changes in expression of VLA-4 (on lymphocytes) or L-selectin (on lymphocytes or neutrophils) (data not shown).

**Pathological evaluation.** The guinea pig lungs were perfused and fixed using an adaptation of the method described by Bassett and Fisher (48). In brief, the whole animal was exsanguinated by perfusing the hepatic portal vein with warm saline and by cutting the dorsal aorta. The lungs were then directly perfused with warm 0.9% saline via the pulmonary artery until they were white. The lungs were fixed by way of the pulmonary artery using warmed fixative (1% glutaraldehyde, 1% paraformaldehyde, and 1% sucrose in 0.1 M cacodylate buffer; pH 7.2–7.4). The fixation procedure lasted for 15 min at a rate of  $10\text{--}12 \text{ ml}\cdot\text{min}^{-1}$  (Masterflex pump system; Cole-Palmer Instrument Co., Chicago, IL) with the lung volume set at functional residual capacity. Transverse sections from the trachea and from each lobe of the lung (3–5 mm thickness) were taken for pathological evaluation. Sections were embedded in glycol methacrylate for light microscopy (JB-4; Polysciences, Inc., Warrington, PA) (49).

**Statistics.** Frequency response curves in control and antigen-challenged guinea pigs were compared using a two-way analysis of variance for repeated measures. Dose–response curves to gallamine in control and antigen-challenged guinea pigs were also compared using a two-way analysis of variance for repeated measures. The initial bronchoconstrictor responses to stimulation of the vagus nerves between control and antigen-challenged guinea pigs were compared by using unpaired Student's *t* tests (50). The differences in cells recovered from either BAL or peripheral blood between treatment groups


were tested by use of a one-factor analysis of variance (50).  $P < 0.05$  was considered significant.

## Results


Several of the sensitized nonantibody-treated animals were injected with intravenous ovalbumin after measuring the function of the neuronal  $M_2$  muscarinic receptors. This injection caused a sustained bronchoconstriction (in excess of  $500 \text{ mm H}_2\text{O}$ ), confirming that these animals were sensitized to ovalbumin (antibody-treated guinea pigs were not tested in this manner since the resulting bronchoconstriction makes lavage impossible.) In the antibody-treated guinea pigs, leukocytes were obtained at the end of the experiments, and saturation with antibody was confirmed by flow cytometry (Fig. 1).

In the absence of electrical stimulation of the vagus nerves, baseline Ppi was not significantly different among control animals ( $113.1 \pm 5.1 \text{ mm H}_2\text{O}$ ), animals that were sensitized and challenged with ovalbumin ( $126.6 \pm 4.5 \text{ mm H}_2\text{O}$ ), challenged animals pretreated with HP1/2 ( $140.5 \pm 14.4 \text{ mm H}_2\text{O}$ ), or challenged animals pretreated with LAM1-116 ( $105.4 \pm 8.6 \text{ mm H}_2\text{O}$ ). Likewise, there was no significant difference in baseline heart rate among control animals ( $294.3 \pm 6.2 \text{ beats}\cdot\text{min}^{-1}$ ), animals that were sensitized and challenged with ovalbumin ( $301.4 \pm 8.9 \text{ beats}\cdot\text{min}^{-1}$ ), challenged animals pretreated with HP1/2 ( $279.3 \pm 7.8 \text{ beats}\cdot\text{min}^{-1}$ ), or challenged animals pretreated with LAM1-116 ( $307.5 \pm 11.1 \text{ beats}\cdot\text{min}^{-1}$ ).

Simultaneous electrical stimulation of both vagus nerves resulted in bronchoconstriction, which was rapidly reversed after electrical stimulation of the nerves was stopped. Electrical stimulation of the nerves (10 V, 0.2 ms, 5-s duration, 2–15 Hz) produced a frequency-dependent increase in vagally induced bronchoconstriction in control animals (Fig. 2, *open squares*). This increase was significantly greater in animals that had been sensitized and challenged (Fig. 2, *closed squares*). Pretreatment with HP1/2 prevented the increased response to electrical stimulation of the nerves (Fig. 2, *closed circles*).



**Figure 1.** Flow cytometric analysis of VLA-4 and L-selectin expression on guinea pig peripheral blood lymphocytes. Blood was obtained 24 h after daily administration of  $4 \text{ mg}\cdot\text{kg}^{-1}$  of either HP1/2 or LAM1-116 for four consecutive days, and leukocytes were labeled by incubation in vitro with FITC anti-mouse IgG (displayed as in vitro). For comparison, blood was simultaneously obtained from a nonantibody-treated animal, and was labeled in vitro with HP1/2 or LAM1-116, followed by incubation in vitro with FITC anti-mouse IgG (displayed as in vitro). Lymphocytes were identified based on their typical light scatter characteristics. Data are representative of three separate experiments yielding similar results.




**Figure 2.** The potentiation of vagally induced bronchoconstriction after antigen challenge is inhibited by pretreatment with the mAb HP1/2. In control animals (*open squares*), electrical stimulation of the vagus nerves (10 V, 0.2 ms, 5 s) at increasing frequencies (2–15 Hz) causes frequency-dependent bronchoconstriction, measured as an increase in pulmonary inflation pressure in mm H<sub>2</sub>O. Frequency-dependent bronchoconstriction was significantly greater in animals that had been antigen-challenged (*closed squares*), but was not different from control in animals pretreated with the mAb HP1/2 before antigen challenge (*closed circles*). Each point is the mean  $\pm$  SEM;  $n = 5$  animals. \*Significantly different from control.

In the absence of gallamine, electrical stimulation of both vagus nerves (15 Hz, 0.2 ms for 5 s; at 1-min intervals) was slightly adjusted (5–20 V), to induce bronchoconstrictions that were similar among groups ( $19.0 \pm 0.9$  mm H<sub>2</sub>O in controls;  $19.4 \pm 1.0$  mm H<sub>2</sub>O in antigen-challenged guinea pigs;  $17.7 \pm 1.0$  mm H<sub>2</sub>O in antigen-challenged guinea pigs pretreated with HP1/2, and  $16.2 \pm 0.6$  mm H<sub>2</sub>O in antigen-challenged guinea pigs pretreated with LAM1-116).

In control animals, gallamine ( $0.1$ – $10$  mg·kg<sup>-1</sup> *iv*) potentiated vagally-induced bronchoconstriction in a dose-dependent fashion by blocking inhibitory M<sub>2</sub> muscarinic receptors on the pulmonary parasympathetic nerves (Fig. 3, *open circles*). The effect of gallamine was quite marked;  $10$  mg·kg<sup>-1</sup> increased vagally induced bronchoconstriction fivefold. In contrast, potentiation of vagally induced bronchoconstriction by gallamine was significantly attenuated in sensitized, challenged animals (Fig. 3, *solid circles*). In those animals pretreated with HP1/2 before antigen challenge, the response to gallamine was not significantly different from the controls (Fig. 3, *solid triangles*). Pretreatment with LAM1-116 before antigen challenge did not affect the response of the antigen-challenged animals to gallamine (Fig. 3, *solid, upside-down triangles*).

In the heart, gallamine caused a dose-related inhibition of vagally induced bradycardia. The effect of gallamine on vagally induced bradycardia was not different among control, sensitized, and challenged or challenged animals pretreated with HP1/2 or LAM1-116 (data not shown).

Antigen challenge significantly increased the total number of inflammatory cells recovered from the lungs by bronchoalveolar lavage (the volume recovered was not different be-




**Figure 3.** The potentiation of vagally-induced bronchoconstriction by gallamine is protected by pretreatment with HP1/2 in antigen-challenged animals. In the absence of gallamine, electrical stimulation of the vagus nerves (15 Hz, 0.2 ms,  $9.5 \pm 0.78$  V, 75 pulses/train) causes bronchoconstriction measured as a rise in pulmonary inflation pressure in mm H<sub>2</sub>O. There was no significant difference between these groups. Gallamine potentiates vagally induced bronchoconstriction in control animals (*open circles*), but not in antigen-challenged animals (*solid circles*;  $P < 0.0001$ ). In antigen-challenged guinea pigs pretreated with HP1/2, gallamine potentiated vagally-induced bronchoconstriction (*upturned solid triangles*). There was no significant difference between control guinea pigs and antigen-challenged guinea pigs that were pretreated with HP1/2, but there was a difference between the HP1/2-treated and untreated antigen-challenged groups;  $P < 0.0006$ . Pretreatment with LAM1-116 did not significantly affect the response of the antigen-challenged animals to gallamine. The results are expressed as a ratio of vagally induced bronchoconstriction in the presence of gallamine to vagally induced bronchoconstriction in the absence of gallamine. Each point is the mean  $\pm$  SEM;  $n = 5$  animals. \*Significantly different from control; †significantly different from antigen-challenged.

tween groups). This increase was comprised primarily of eosinophils (Fig. 4, compare solid to open bars). Pretreatment with HP1/2 before antigen challenge inhibited this increase in eosinophils without affecting the number of macrophages, neutrophils, or lymphocytes in the lavage fluid (Fig. 4, compare hatched bars to solid bars). Pretreatment with LAM1-116 before antigen challenge did not significantly inhibit the influx of eosinophils (Fig. 4).

Histological examination of airways demonstrated that eosinophils were also increased in the lungs of antigen-challenged guinea pigs. There were few inflammatory cells in the airways of control guinea pigs. Similarly, there were no eosinophils around the nerve bundles below the airway smooth muscle (Fig. 5). In contrast, in antigen-challenged guinea pigs, the airways, particularly the area around the nerves, were filled with inflammatory cells, primarily eosinophils (Fig. 6). Eosinophilic inflammation of the nerve bundles was blocked in the guinea pigs pretreated with HP1/2 (Fig. 7), but was not blocked by pretreatment with LAM1-116 (Fig. 8).

Antigen challenge in the absence or presence of LAM1-116 did not affect the number or types of circulating leukocytes





**Figure 4.** Treatment with HP1/2 inhibited the influx of eosinophils into the lungs following antigen challenge. The total number of inflammatory cells obtained from bronchoalveolar lavage (BAL) was significantly increased in the challenged guinea pigs (solid bars) compared with the controls (open bars). This increase was predominantly eosinophils. Treatment with HP1/2 (dashed bars) prevented the increase in total inflammatory cells and in eosinophils. Treatment with LAM1-116 (striped bar) did not significantly affect either the increase in total cells or the increase in eosinophils. Data are expressed as the mean  $\pm$  SEM,  $n = 5$ . \*Significantly different from control; †significantly different from antigen-challenged.

measured 24 h after the fourth antigen challenge (which coincides with 24 h after the fourth mAb dose). Pretreatment with HP1/2, however, significantly increased the number of circulating leukocytes at this same time point. This increase appeared to be made up predominantly of lymphocytes (Fig. 9).

## Discussion

In the lungs, neuronal  $M_2$  muscarinic receptors normally function to inhibit release of acetylcholine from the parasympathetic nerves. These receptors are important neuromodulators of nerve function, since in control (unchallenged) guinea pigs, blockade by gallamine potentiated vagally induced bronchoconstriction fivefold. These data confirm previous findings (15). In contrast, the gallamine-induced potentiation of vagally induced bronchoconstriction was markedly attenuated after antigen challenge. These results confirm that the function of neuronal  $M_2$  receptors in the lung is impaired after antigen challenge (16, 21).

Since neuronal  $M_2$  muscarinic receptors inhibit acetylcholine release, loss of  $M_2$  receptor function is a potential mechanism for antigen-induced hyperresponsiveness. Frequency response curves were significantly potentiated after antigen challenge (Fig. 2), indicating that the animals were hyperresponsive. Pretreatment of sensitized guinea pigs with the mAb HP1/2, but not with the mAb LAM1-116, prevented loss of  $M_2$  muscarinic receptor function in antigen-challenged animals (Fig. 3). In addition, pretreatment with the mAb HP1/2 also prevented the increase in hyperreactivity after antigen challenge (Fig. 2). These data strongly suggest that the hyperre-




**Figure 5.** There are few inflammatory cells and no eosinophils around the nerves in lungs from control guinea pigs. Sections of lung were embedded in methacrylate, sectioned, and stained with hematoxylin and eosin. A nerve bundle (arrow) is shown lying under the airway smooth muscle under low (top) and high magnification (bottom).


sponsiveness to nerve stimulation after antigen challenge is mediated by loss of neuronal  $M_2$  muscarinic receptor function.

The effects of HP1/2 on the function of the neuronal  $M_2$  receptors could not be accounted for by changes in baseline resistance, since baseline Ppi was the same in control and in antigen-challenged guinea pigs in the absence and presence of HP1/2 (or LAM1-116). Circulating inflammatory cells were not altered by antigen challenge, or by treatment with any of the antibodies (with the exception of lymphocytes, which were increased following treatment with HP1/2) (Fig. 9).

The increase in circulating lymphocytes after HP1/2 is a consistent finding in many animal models (51). The mechanism responsible for this increase is unknown. While it was initially assumed that these effects were due to interference with normal lymphocyte recirculation patterns to mesenteric sites via blockade of  $\alpha_4 \beta_7$  function, this assumption does not appear to be the case (52). Although inhibition of lymphocyte recruitment to the airways has been seen with  $\alpha_4$  integrin antibody treatment in a mouse model of allergic airways disease



**Figure 6.** Inflammatory cells are present in the lungs of guinea pigs that have been sensitized and challenged with antigen. Lung tissue was processed as in Fig. 5. A nerve bundle (*arrow*) is shown lying under the airway smooth muscle under low (*top*) and high magnification (*bottom*). In these antigen-challenged guinea pigs, eosinophils (*e*) surround the nerves.



**Figure 7.** The lungs of guinea pigs that have been treated with HP1/2 before antigen challenge have a marked absence of eosinophils around their nerves. Lung tissue was processed as in Fig. 5. A nerve bundle (*arrow*) is shown lying under the airway smooth muscle under low (*top*) and high magnification (*bottom*).



(9), this inhibition was not observed in our study. Therefore, it seems unlikely that the lymphocytosis seen in the present experiments was due to the inhibition of lymphocyte migration into the airways.

Antigen challenge is associated with inflammation, particularly by eosinophils, of the airways and lungs (5, 8–11). Bronchoalveolar lavage of the airways showed a selective and significant increase in the numbers of eosinophils in the challenged guinea pigs when compared with the controls. This increase was inhibited by pretreatment with the antibody HP1/2, but not by pretreatment with the antibody LAM1-116 (Fig. 3). In addition, histological examination of the airways of challenged guinea pigs showed an accumulation of eosinophils around the nerves of the challenged animals that was inhibited by pretreatment with HP1/2, but not by LAM1-116. Thus, pretreatment with a VLA-4 mAb selectively inhibited eosinophil migration into the airways of antigen-challenged guinea pigs, and this inhibition was associated with the protected function of the neuronal  $M_2$  muscarinic receptors. Conversely, the anti-

body to L-selectin, LAM1-116, had no effect on either eosinophil migration, or on  $M_2$  muscarinic receptor function.

Other studies have demonstrated that inhibition of eosinophil influx into the airways prevents antigen-induced hyperresponsiveness (11, 53). We have confirmed these studies by demonstrating that the mAb HP1/2 also prevents antigen-induced hyperresponsiveness. Furthermore, we have demonstrated that inhibition of eosinophil influx into the airways prevents antigen-induced loss of  $M_2$  muscarinic receptor function. Since loss of receptor function causes hyperresponsiveness of the vagus nerves (15–17), and thus hyperresponsiveness to any challenge that has a vagal component, eosinophils may induce hyperreactivity by interfering with neuronal  $M_2$  muscarinic receptor function.

The inability of the L-selectin mAb LAM1-116 to prevent eosinophil recruitment into the lung, and to prevent allergen-induced changes in  $M_2$  muscarinic receptor function, strongly suggests that L-selectin function is not critical for eosinophil migration into the lung in this model. L-selectin blockade with




**Figure 8.** The lungs of guinea pigs that have been treated with LAM1-116 before antigen challenge still demonstrate eosinophils (*e*) around their nerves. Lung tissue was processed as in Fig. 5. A nerve bundle (*arrow*) is shown lying under the airway smooth muscle under low (*top*) and high magnification (*bottom*).

mAb both in vitro and in vivo has been shown to reduce eosinophil rolling responses (38, 39). In other animal models, attenuation of L-selectin function or expression clearly reduces neutrophil recruitment (41, 54–57). The inability of LAM1-116 to block eosinophil recruitment was not due to inadequate dosing, because maintenance of saturating serum levels was verified by flow cytometry (Fig. 1). Furthermore, the LAM1-116 mAb, when administered at similar doses, has been used successfully in mouse models to prevent leukocyte influx into sites of inflammation (Steeber, D.A., and T.F. Tedder, unpublished data). Thus, it may be possible that L-selectin is more important in neutrophil recruitment responses than for eosinophil recruitment.

Since LAM1-116 had no effect on eosinophil influx in antigen-challenged guinea pigs, any possible concerns that irrelevant, nonbinding isotype-matched mAb (used as protein controls in previous studies) might have yielded different results, can be eliminated.

Since eosinophils surround the nerves of antigen-challenged guinea pigs, we have previously suggested that eosinophils



**Figure 9.** In the peripheral blood, there was no statistical difference in circulating leukocyte numbers 24 h after the fourth day of experimentation among the control (*open bars*), challenged (*solid bars*), or LAM1-116 treated and challenged (*striped bars*) groups. Pretreatment with HP1/2 (*dashed bars*), however, increased the total number of circulating lymphocytes in the challenged animals. Data are expressed as the mean  $\pm$  SEM, *n* = 5. \* Significantly different from control.

play an important role in antigen-induced loss of  $M_2$  muscarinic receptor function (19). Eosinophil major basic protein has been identified immunohistologically in the nerve bundles of antigen-challenged guinea pigs, and in humans with asthma (18, 58). Both eosinophil major basic protein and eosinophil peroxidase are allosteric antagonists of the  $M_2$  muscarinic receptor (20). An association between eosinophil products and loss of  $M_2$  muscarinic receptor function in vivo was first suggested by the demonstration that polyanionic substances such as heparin, that bind and neutralize eosinophil major basic protein in vitro, acutely restore  $M_2$  receptor function in vivo (21). Thus, eosinophil major basic protein and eosinophil peroxidase may act as endogenous inhibitors of  $M_2$  receptor function. Selective depletion of eosinophils using a mAb against interleukin-5 also protects neuronal  $M_2$  muscarinic receptors, supporting a role for eosinophils in loss of receptor function (19).

The mechanisms of eosinophil recruitment to the nerves in the lungs are unknown. There is now extensive evidence in the literature that the receptor for VLA-4, VCAM-1, is expressed at sites of allergic inflammation in vivo. Allergen challenge of allergic individuals activates the vascular endothelium to express adhesion molecules including VCAM-1 (32, 59, 60); a significant correlation between VCAM-1 staining and eosinophil influx is often seen. There is also indirect evidence that VCAM-1 expression occurs within the human airway after endoscopic intrabronchial antigen challenge, since increased levels of a soluble form of VCAM-1 has been detected in BAL fluids (61). Additional experiments implicate VCAM-1 in the pathophysiology of allergic rhinitis and asthma in humans. In one such study, strong endothelial staining for VCAM-1, as well as for ICAM-1, was observed in endobronchial biopsy specimens from symptomatic patients with asthma (33). Studies of nasal airway tissue from subjects with perennial allergic rhinitis have modestly increased expression of VCAM-1 com-



pared with tissues from nonallergic controls, and significant VCAM-1 staining has been reported in nasal polyps, tissues extensively infiltrated by eosinophils (31, 34).

In the nerves, VCAM-1 can be expressed after incubation with tumor necrosis factor (62). Thus, it is possible that cytokine-induced VCAM-1 expression might play a role in the observed association between eosinophils and airway nerves. It is also tempting to speculate that antigen challenge induces VCAM-1 expression in the airways, and may also induce expression by the nerves in the airway.

Alternatively, another ligand for VLA-4 is a form of alternatively spliced fibronectin containing CS-1 (63). While VLA-4 binds less well to fibronectin than to VCAM-1, fibronectin is expressed by the microvasculature (64, 65), and it is possible that it may be involved in localizing eosinophils within the lung.

Once the eosinophils have migrated out of the vasculature, many localize to the nerves within the airways (18, 58). These eosinophils subsequently release granule proteins, including eosinophil major basic protein and eosinophil peroxidase, which by inhibiting neuronal M<sub>2</sub> muscarinic receptors, increase release of acetylcholine from the vagus nerves, resulting in antigen-induced hyperresponsiveness. Blockade of VLA-4 with the mAb HP1/2 inhibits migration of eosinophils, protecting the neuronal M<sub>2</sub> muscarinic receptors, and preventing antigen-induced hyperresponsiveness.

Although antibody-blocking data for allergic diseases in humans is lacking, blocking mAbs to VLA-4 have been infused in vivo in a variety of animal models of eosinophilic allergic inflammatory conditions of the lung (9, 11, 37, 53, 66–68). In general, these studies agree that pretreatment with VLA-4 mAb will reduce or prevent eosinophil influx into the lungs, and prevent the physiological changes that accompany this reaction. An example of an exception to this rule was seen in the sheep model, where infusion of a VLA-4 antibody prevented late-phase changes in airway function without affecting eosinophil recruitment as assessed by BAL (53).

In conclusion, the data presented here delineate the role of VLA-4, and not L-selectin, in allergen-induced eosinophil recruitment to the guinea pig airway, in the localization of recruited eosinophils to nerves, and in the alteration in neuronal M<sub>2</sub> muscarinic receptor function and subsequent hyperresponsiveness. While other mediators, such as eotaxin and other C-C chemokines (69–71), may also be important in eosinophil recruitment and localization in the airways, eosinophil VLA-4, presumably via its interactions with counterligands VCAM-1 (and perhaps fibronectin) appears to be critical in the recruitment response, and lends support to the concept that VLA-4 antagonists may prove useful in the treatment of allergic diseases (51).

## Acknowledgments

The authors wish to thank Sherry Sterbinsky for expert technical assistance in flow cytometry. Authors also wish to thank Dr. George Jakab for the use of his inhalational facilities and Brian Schofield for his assistance with the histology. Both laboratories were supported by NIH grant ES-03819.

This work was funded by National Institute of Health grants HL-44727, HL-55543 (Dr. Fryer), HL-49545 (Dr. Bochner), CA-54464, HL-50985, AI-26872 (Dr. Tedder), and AI-07217 (Dr. Steeber), and by grants from the Burroughs Wellcome Fund (Dr. Bochner) and the Council for Tobacco Research (Dr. Fryer). Dr. Tedder is a scholar of the Leukemia Society of America.

## References

1. Hirshman, C.A., and H. Downes. 1993. Experimental asthma in animals. *In* *Bronchial Asthma*. 3rd ed. E.B. Weiss and M. Stein, editors. Little, Brown and Co., Boston, MA. 382–404.
2. DeMonchy, J.G.R., H.F. Kauffman, P. Venge, G.H. Koeter, H.M. Jansen, H.J. Sluiter, and K. DeVries. 1985. Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions. *Am. Rev. Respir. Dis.* 131:373–376.
3. Dunn, C.J., G.A. Elliott, J.A. Oostveen, and I.M. Richards. 1988. Development of a prolonged eosinophil-rich inflammatory leukocyte infiltration in the guinea pig asthmatic response to ovalbumin inhalation. *Am. Rev. Respir. Dis.* 137:541–547.
4. Ishida, K., L.J. Kelly, R.J. Thomson, L.L. Beattie, and R.R. Schellenberg. 1989. Repeated antigen challenge induces airway hyperresponsiveness with tissue eosinophilia in guinea-pigs. *J. Appl. Physiol.* 67:1133–1139.
5. Gulbenkian, A.R., X. Fernandez, W. Kreutner, M. Minnicozzi, A.S. Watanick, T. Kung, and R.W. Egan. 1990. Anaphylactic challenge causes eosinophil accumulation in bronchoalveolar lavage fluid of guinea pigs: Modulation by betamethasone, phenidone, indomethacin, WEB 2086, and a novel antiallergy agent, SCH 37224. *Am. Rev. Respir. Dis.* 142:680–685.
6. Laitinen, L.A., A. Laitinen, M. Heino, and T. Haahtela. 1991. Eosinophilic airway inflammation during exacerbation of asthma and its treatment with inhaled corticosteroid. *Am. Rev. Respir. Dis.* 143:423–427.
7. Rossi, G.A., E. Crimi, S. Lantero, P. Gianioro, S. Oddera, P. Crimi, and V. Brusasco. 1991. Late-phase asthmatic reaction to inhaled allergen is associated with early recruitment of eosinophils in the airways. *Am. Rev. Respir. Dis.* 144:379–383.
8. Gundel, R.H., C.D. Wegner, and L.G. Letts. 1992. Antigen-induced acute and late phase responses in primates. *Am. Rev. Respir. Dis.* 146:369–373.
9. Nakajima, H., H. Sano, T. Nishimura, S. Yoshida, and I. Iwamoto. 1994. Role of vascular cell adhesion molecule-1/very late activation antigen-4 and intercellular adhesion molecule-1/lymphocyte function-associated antigen-1 interactions in antigen-induced eosinophil and T-cell recruitment into the tissue. *J. Exp. Med.* 179:1145–1154.
10. Mauser, P.J., A.M. Pitman, X. Fernandez, S.K. Foran, G.K. Adams, W. Kreutner, R.W. Egan, and R.W. Chapman. 1995. Effects of an antibody to interleukin-5 in a monkey model of asthma. *Am. J. Respir. Crit. Care Med.* 152:467–472.
11. Pretolani, M., C. Ruffie, J.R. Lapa e Silva, D. Joseph, R.R. Lobb, and B.B. Varghantig. 1994. Antibody to very late activation antigen 4 prevents antigen-induced bronchial hyperreactivity and cellular infiltration in the guinea pig airways. *J. Exp. Med.* 180:795–805.
12. Nadel, J.A., and P.J. Barnes. 1984. Autonomic regulation of the airways. *Annu. Rev. Med.* 35:451–467.
13. Barnes, P.J., P. Minette, and J. Maclagan. 1988. Muscarinic receptor subtypes in the airways. *TIBS (Trends, Biochem. Sci.)* 9:412–416.
14. Roffel, A.F., C.R.S. Elzinga, and J. Zaagsma. 1990. Muscarinic M3 receptors mediate contraction of human central and peripheral airway smooth muscle. *Pulmon. Pharmacol.* 3:47–51.
15. Fryer, A.D., and J. Maclagan. 1984. Muscarinic inhibitory receptors in pulmonary parasympathetic nerves in the guinea-pig. *Br. J. Pharmacol.* 83:973–978.
16. Fryer, A.D., and M. Wills-Karp. 1991. Dysfunction of M2 muscarinic receptors in pulmonary parasympathetic nerves after antigen challenge in guinea-pigs. *J. Appl. Physiol.* 71:2255–2261.
17. Baker, D., H. Don, and J. Brown. 1992. Direct measurement of acetylcholine release in guinea-pig trachea. *Am. J. Physiol.* 263:L142–L147.
18. Costello, R.W., B.H. Schofield, D.B. Jacoby, and A.D. Fryer. 1995. Parasympathetic nerves are infiltrated with eosinophils in antigen challenged guinea-pigs. *Am. J. Respir. Crit. Care Med.* 151:818a. (Abstr.)
19. Elbon, C.L., D.B. Jacoby, and A.D. Fryer. 1995. Pretreatment with an antibody to interleukin-5 prevents loss of pulmonary M2 muscarinic receptor function in antigen challenged guinea-pigs. *Am. J. Respir. Cell Mol. Biol.* 12:320–328.
20. Jacoby, D.B., G.J. Gleich, and A.D. Fryer. 1993. Human eosinophil major basic protein is an endogenous allosteric antagonist at the inhibitory muscarinic M2 receptor. *J. Clin. Invest.* 91:1314–1318.
21. Fryer, A.D., and D.B. Jacoby. 1992. Function of pulmonary M2 muscarinic receptors in antigen-challenged guinea-pigs is restored by heparin and poly-L-glutamate. *J. Clin. Invest.* 90:2292–2298.
22. Frigas, E., D.A. Loegering, and G.J. Gleich. 1980. Cytotoxic effect of the guinea pig major basic protein on tracheal epithelium. *Lab Invest.* 42:35–43.
23. Barker, R.L., R.H. Gundel, G.J. Gleich, J.L. Checkel, D.A. Loegering, L.R. Pease, and K.J. Hamann. 1991. Acidic polyamino acids inhibit eosinophil granule major basic protein toxicity. *J. Clin. Invest.* 88:798–805.
24. Bochner, B.S., and R.P. Schleimer. 1994. The role of adhesion molecules in human eosinophil and basophil recruitment. *J. Allergy Clin. Immunol.* 94:427–438.
25. Bochner, B.S., F.W. Luscinskas, M.A. Gimbrone, Jr., W. Newman, S.A. Sterbinsky, C. Darse-Anthony, D. Klunk, and R.P. Schleimer. 1991. Adhesion of human basophils, eosinophils, and neutrophils to IL-1-activated human vascular endothelial cells: contributions of endothelial cell adhesion molecules. *J. Exp. Med.* 173:1553–1557.

26. Dobrina, A., R. Menegazzi, T.M. Carlos, E. Nardon, R. Cramer, T. Zachi, J.M. Harlan, and P. Patriarca. 1991. Mechanisms of eosinophil adherence to cultured vascular endothelial cells: eosinophils bind to the cytokine-induced endothelial ligand vascular cell adhesion molecule-1 via the very late activation antigen-4 integrin receptor. *J. Clin. Invest.* 88:20-26.
27. Walsh, G.M., J. Mermod, A. Hartnell, A.B. Kay, and A.J. Wardlaw. 1991. Human eosinophil, but not neutrophil, adherence to IL-1-stimulated human umbilical vascular endothelial cells is  $\alpha 4\beta 1$  (very late antigen-4) dependent. *J. Immunol.* 146:3419-3423.
28. Weller, P.F., T.H. Rand, S.E. Goelz, G. Chi-Rosso, and R.R. Lobb. 1991. Human eosinophil adherence to vascular endothelium mediated by binding to vascular cell adhesion molecule 1 and endothelial leukocyte adhesion molecule 1. *Proc. Natl. Acad. Sci. USA.* 88:7430-7433.
29. Elices, M.J., L. Osborn, Y. Takada, C. Crouse, S. Luhowskyj, M.E. Hemler, and R.R. Lobb. 1990. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. *Cell.* 60:577-584.
30. Nagata, M., J.B. Sedgwick, M.E. Bates, H. Kita, and W.W. Busse. 1995. Eosinophil adhesion to vascular cell adhesion molecule-1 activates superoxide anion generation. *J. Immunol.* 155:2194-2202.
31. Montefort, S., I.H. Feather, S.J. Wilson, D.O. Haskard, T.H. Lee, S.T. Holgate, and P.H. Howarth. 1992. The expression of leukocyte-endothelial adhesion molecules is increased in perennial allergic rhinitis. *Am. J. Respir. Cell Mol. Biol.* 7:393-398.
32. Lee, B.-J., R.M. Naclerio, B.S. Bochner, R.M. Taylor, M.C. Lim, and F.M. Baroody. 1994. Nasal challenge with allergen upregulates the local expression of vascular endothelial adhesion molecules. *J. Allergy Clin. Immunol.* 94:1006-1016.
33. Ohkawara, Y., K. Yamauchi, N. Maruyama, H. Hoshi, I. Ohno, M. Honma, Y. Tanno, G. Tamura, K. Shirato, and H. Ohtani. 1995. In situ expression of the cell adhesion molecules in bronchial tissues from asthmatics with air-flow limitation: in vivo evidence of VCAM-1/VLA-4 interaction in selective eosinophil infiltration. *Am. J. Respir. Cell Mol. Biol.* 12:4.
34. Jahnsen, F.L., G. Haraldsen, J.P. Aanesen, R. Høy, and P. Brandtzaeg. 1995. Eosinophil infiltration is related to increased expression of vascular cell adhesion molecule-1 in nasal polyps. *Am. J. Respir. Cell Mol. Biol.* 12:624-632.
35. Fukuda, T., Y. Fukushima, T. Numao, N. Ando, M. Arima, H. Nakajima, H. Sagara, T. Adachi, S. Motojima, and S. Makino. 1996. Role of interleukin-4 and vascular cell adhesion molecule-1 in selective eosinophil migration into the airways in allergic asthma. *Am. J. Respir. Cell Mol. Biol.* 14:84-94.
36. Beck, L.A., C. Stellato, L.D. Beall, T.J. Schall, D. Leopold, C.A. Bickel, F. Baroody, B.S. Bochner, and R.P. Schleimer. 1996. Detection of the chemokine RANTES and endothelial adhesion molecules in nasal polyps. *J. Allergy Clin. Immunol.* 98:766-780.
37. Weg, V.B., T.J. Williams, R.R. Lobb, and S. Nourshargh. 1993. A monoclonal antibody recognizing very late activation antigen-4 inhibits eosinophil accumulation in vivo. *J. Exp. Med.* 177:561-566.
38. Knol, E.F., F. Tackey, T.F. Tedder, D.A. Klunk, C.A. Bickel, and B.S. Bochner. 1994. Comparison of human eosinophil and neutrophil adhesion to endothelial cells under non-static conditions: the role of L-selectin. *J. Immunol.* 153:2161-2167.
39. Sriramaramo, P., U.H. von Andrian, E.C. Butcher, M.A. Bourdon, and D.H. Broide. 1994. L-selectin and very late antigen-4 integrin promote eosinophil rolling at physiological shear rates in vivo. *J. Immunol.* 153:4238-4246.
40. Arbones, M.L., D. Ord, K. Ley, H. Ratech, C. Maynard-Curry, G. Otten, D. Capon, and T.F. Tedder. 1994. Lymphocyte homing and leukocyte rolling and migration are impaired in L-selectin deficient mice. *Immunity.* 1:247-280.
41. Tedder, T.F., D.A. Steeber, and P. Pizcueta. 1995. L-selectin deficient mice have impaired leukocyte recruitment into inflammatory sites. *J. Exp. Med.* 181:2259-2264.
42. Green, C.J. 1982. Animal Anaesthesia. Laboratory Animal Handbooks, Laboratory Animals Ltd. London. 8:81-82.
43. Dixon, W.E., and T.G. Brody. 1903. Contributions to the physiology of the lungs. Part 1, the bronchial muscles and their innervation and the action of drugs upon them. *J. Physiol. (Lond.)* 29:97-173.
44. Blaber, L.C., A.D. Fryer, and J. MacLagan. 1985. Neuronal muscarinic receptors attenuate vagally-induced contraction of feline bronchial smooth muscle. *Br. J. Pharmacol.* 86:723-728.
45. Bassett, D.J.P., E. Bowen-Kelly, E.L. Brewster, C.L. Elbon, S.S. Reichenbaugh, T. Bunton, and J.S. Kerr. 1988. A reversible model of acute lung injury based on ozone exposure. *Lung.* 166:355-369.
46. Warr, G.A., and G.J. Jakob. 1983. Pulmonary inflammatory responses during viral pneumonia and secondary bacterial infection. *Inflammation.* 7:93-104.
47. Davenpeck, K.L., F.J. Chrest, S.A. Sterbinsky, C.A. Bickel, and B.S. Bochner. 1995. Carboxyfluorescein diacetate labeling does not affect adhesion molecule expression or function in human neutrophils or eosinophils. *J. Immunol. Methods.* 188:79-89.
48. Bassett, D.J.P., and A.B. Fisher. 1976. Metabolic responses to carbon monoxide by isolated rat lungs. *Am. J. Physiol.* 230:658-663.
49. Vogt, Jr., R.F., N.A. Hynes, A.M. Dannenberg Jr., S. Castracane, and L. Weiss. 1983. Improved techniques using giemsa stained glycol methacrylate tissue sections to quantitate basophils and other leukocytes in inflammatory skin lesions. *Stain Technol.* 58:193-205.
50. Zar, J.H. 1974. Biostatistical Analysis. Prentice-Hall, Englewood Cliffs, NJ. 121-162.
51. Lobb, R.R., and M.E. Hemler. 1994. The pathophysiological role of  $\alpha 4$  integrins in vivo. *J. Clin. Invest.* 94:1722-1728.
52. Hamann, A., D.P. Andrew, D. Jablonki-Westrich, B. Holtzman, and E.C. Butcher. 1984. Role of alpha (4) integrins in lymphocyte homing to mucosal tissues in vivo. *J. Immunol.* 152:3282-3293.
53. Abraham, W.M., M.W. Sielczak, A. Ahmed, I.T. Cortes, I.T. Lauredo, J. Kim, B. Pepinsky, C.D. Benjamin, D.R. Leone, R.R. Lobb, and P.F. Weller. 1994. Alpha 4-integrins mediate antigen-induced late bronchial responses and prolonged airway hyperresponsiveness in sheep. *J. Clin. Invest.* 93:776-787.
54. Jutila, M.A., L. Rott, E.L. Berg, and E.C. Butcher. 1989. Function and regulation of the neutrophil MEL-14 antigen in vivo: comparison with LFA-1 and MAC-1. *J. Immunol.* 143:3318-3324.
55. Watson, S.R., C. Fennie, and L.A. Lasky. 1991. Neutrophil influx into an inflammatory site inhibited by a soluble homing receptor-IgG chimera. *Nature (Lond.)* 349:164-167.
56. Mihelcic, D., B. Schleiffenbaum, T.F. Tedder, S.R. Sharar, J.M. Harlan, and R.K. Winn. 1994. Inhibition of leukocyte L-selectin function with a monoclonal antibody attenuates reperfusion injury to the rabbit ear. *Blood.* 84:2322-2328.
57. Mulligan, M.S., M. Miyasaka, T. Tamatani, M.L. Jones, and P.A. Ward. 1994. Requirements for L-selectin in neutrophil-mediated lung injury in rats. *J. Immunol.* 152:832-840.
58. Costello, R.W., G.M. Kephart, A.D. Fryer, D.B. Jacoby, and G.J. Gleich. 1996. Airway nerves of patients with asthma are infiltrated with eosinophils and extracellular major basic protein. *Am. J. Respir. Crit. Care Med.* 153:847a. (Abstr.)
59. Kyan-Aung, U., D.O. Haskard, R.N. Poston, M.H. Thornhill, and T.H. Lee. 1991. Endothelial leukocyte adhesion molecule-1 and intracellular adhesion molecule-1 mediate the adhesion of eosinophils to endothelial cells in vitro and are expressed by endothelium in allergic cutaneous inflammation in vivo. *J. Immunol.* 146:521.
60. Bentley, A.M., S.R. Durham, D.S. Robinson, G. Menz, C. Storz, O. Cromwell, B. Kay, and A.J. Wardlaw. 1993. Expression of endothelial and leukocyte adhesion molecules, intercellular adhesion molecule-1, E-selectin, and vascular cell adhesion molecule-1 in the bronchial mucosa in steady-state and allergen-induced asthma. *J. Allergy Clin. Immunol.* 92:857-868.
61. Zangrilli, J.G., J.R. Shaver, R.A. Cirelli, S.K. Cho, C.G. Garlis, A. Falcone, F.M. Cuss, J.E. Fish, and S.P. Peters. 1995. sVCAM-1 levels after segmental challenge correlate with eosinophil influx, IL-4 and IL-5 production, and the late phase response. *Am. J. Respir. Crit. Care Med.* 151:1346-1353.
62. Birdsall, H.H., C. Lane, M.N. Ramser, and D.C. Anderson. 1992. Induction of VCAM-1 and ICAM-1 on human neural cells and mechanisms of mononuclear leukocyte adhesion. *J. Immunol.* 148:2717-2723.
63. Walsh, G.M., F.A. Symon, and A.J. Wardlaw. 1995. Human eosinophils preferentially survive on tissue fibronectin compared with plasma fibronectin. *Clin. Exp. Allergy.* 25:1128-1136.
64. Elices, M.J., V. Tsai, D. Strahl, A.S. Goel, V. Tollefson, T. Arrhenius, E.A. Wayner, F.C.A. Gaeta, J.D. Fikes, and G.S. Firestein. 1994. Expression and functional significance of alternatively spliced CS-1 fibronectin in rheumatoid arthritis microvasculature. *J. Clin. Invest.* 93:405-416.
65. Metzger, W.J. 1995. Therapeutic approaches based on VLA-4 integrin and its counter receptors. *Springer Semin. Immunopathol.* 16:467-478.
66. Rabb, H.A., R. Olivenstein, T.B. Issekutz, P.M. Renzi, and J.G. Martin. 1994. The role of the leukocyte adhesion molecules VLA-4, LFA-1 and Mac-1 in allergic airway responses in the rat. *Am. J. Respir. Crit. Care Med.* 149:1186-1191.
67. Laberge, S., H.A. Rabb, T.B. Issekutz, and J.G. Martin. 1995. Role of VLA-4 and LFA-1 in allergen-induced airway hyperresponsiveness and lung inflammation in the rat. *Am. J. Respir. Crit. Care Med.* 151:822-829.
68. Das, A.M., T.J. Williams, R. Lobb, and S. Nourshargh. 1995. Lung eosinophilia is dependent on IL-5 and the adhesion molecules CD18 and VLA-4, in a guinea-pig model. *Immunology.* 84:41-46.
69. Griffiths-Johnson, D.A., P.D. Collins, A.G. Rossi, P.J. Jose, and T.J. Williams. 1993. The chemokine, eotaxin, activates guinea-pig eosinophils in vitro and causes their accumulation into the lung in vivo. *Biochem. Biophys. Res. Commun.* 197:1167-1172.
70. Jose, P.J., D.A. Griffiths-Johnson, P.D. Collins, D.T. Walsh, R. Moqbel, N.F. Totty, O. Truong, J.J. Hsuan, and T.J. Williams. 1994. Eotaxin: A potent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammation. *J. Exp. Med.* 179:881-887.
71. Baggiolini, M., and C.A. Dahinden. 1994. CC chemokines in allergic inflammation. *Immunol. Today.* 15:127-133.